Table 5: Studies comparing outcomes of HDCT and CC.

StudyNumber of relapsed pts (only CC)Number of relapsed pts (HDCT)Chemotherapy (prior to HDCT)HDCTSource of stem cellResponse CC (number of patients)Response HDCT (number of patients)EFSOS

Rasper et al. 2014, registry data [14]16153T/C
I/Te
If/E/Ca
C1: busulfan/melphalan
C2: treosulfan/melphalan
NRCR: 14
PR: 20
SD: 12
PD: 72
MD: 43
C1
CR: 5
PR: 2
C2
CR: 19
PR: 8
(before HDCT)
2 years
HDCT: 44–47%
HDCT IN CR/PR: 44%
Without HDCT: 10%
Without HDCT IN CR/PR: 31%
5 years
HDCT: 20–24%
HDCT IN CR/PR: 22%
Without HDCT: 6%
Without HDCT IN CR/PR: 18%
2 years
HDCT: 53–66%
HDCT IN CR/PR: 59%
Without HDCT: 22%
Without HDCT IN CR/PR: 45%
5 years
HDCT: 40–42%
HDCT IN CR/PR: 41%
Without HDCT: 10%
Without HDCT IN CR/PR: 25%

Barker et al. 2005, retrospective [16]4213VDC-IE
VACIME
VDC-A
VDC-A-M
Busulfan/melphalan/thiotepaPBSCCR/PR: 14CR/PR: 13 (before HDCT)5 years
HDCT: 61%
Without HDCT: 7% ()
Without HDCT IN CR/PR: 21% ()
5 years
HDCT: 77%
Without HDCT: 7% ()
Without HDCT IN CR/PR: 22% ()

Palmerini et al. 2009, retrospective [18]3124NLBusulfan/melphalanNLNLNLNL3 yr.
HDCT: 33%
Without HDCT: 22%

Ferrari et al. 2015, retrospective [17]6020High IBusulfan/melphalanPBSCCR: 9
MD: 4
CR/PR: 20 (before HDCT)NL5 yr.
HDCT: 50%
Without HDCT: 5–12%

Bacci et al. 2003, retrospective [3]9835
RO: 33
NoneMelphalan
Busulfan
PBSC
BSC
CR/PR: 2%CR/PR-39% (after HDCT)5-year
HDCT–21.2%
Without HDCT: 0%
mOS
HDCT–27.1 m
Without HDCT 11.1 m

HDCT: high-dose chemotherapy, CC: conventional chemotherapy, ASCT: autologous stem cell transplant, OS: overall survival, EFS: event-free survival, CR: complete remission, PR: partial remission, NL: not listed, T: topotecan, C: cyclophosphamide, I: irinotecan, Te: temozolomide, V: vincristine, E: etoposide, M: methotrexate, A: dactinomycin, If: ifosfamide, D: doxorubicin, Ca: carboplatin, TBI: total body irradiation, high I: high-dose ifosfamide, SD: sustained disease, PD: progressive disease, MD: missing data, and RO: reported outcomes.